Lapyrium
Virac (lapyrium) is a small molecule pharmaceutical. Lapyrium was first approved as Virac rex on 1982-01-01.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Lapyrium chloride
+
Undecoylium chloride iodine complex
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| VIRAC REX | Chesebrough Ponds | N-011914 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
77 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Acromegaly | D000172 | 2 | 4 | 9 | 6 | 5 | 24 | ||
| Neuroendocrine tumors | D018358 | EFO_1001901 | D3A.8 | 3 | 8 | 4 | 3 | 3 | 19 |
| Dumping syndrome | D004377 | EFO_1001307 | K91.1 | — | 1 | — | 1 | — | 2 |
| Congenital hyperinsulinism | D044903 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Carcinoid tumor | D002276 | D3A.00 | — | 2 | 1 | — | — | 3 | |
| Intestinal obstruction | D007415 | K56.60 | — | 2 | 1 | — | — | 3 | |
| Autosomal dominant polycystic kidney | D016891 | EFO_1001496 | Q61.2 | — | 1 | 3 | — | — | 3 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | — | 1 | 1 | — | 1 | 2 |
| Liver diseases | D008107 | EFO_0001421 | K70-K77 | — | 2 | 2 | — | — | 2 |
| Hepatomegaly | D006529 | HP_0002240 | R16.0 | — | 2 | 2 | — | — | 2 |
| Carcinoid heart disease | D002275 | EFO_1001769 | — | — | 1 | — | — | 1 | |
| Growth hormone-secreting pituitary adenoma | D049912 | EFO_0004125 | — | — | 1 | — | — | 1 | |
| Prostatic neoplasms | D011471 | C61 | — | — | 1 | — | — | 1 | |
| Malignant carcinoid syndrome | D008303 | E34.0 | — | — | 1 | — | — | 1 |
Show 7 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Gastrointestinal neoplasms | D005770 | C26.9 | — | 1 | — | — | — | 1 | |
| Pheochromocytoma | D010673 | — | 1 | — | — | — | 1 | ||
| Paraganglioma | D010235 | — | 1 | — | — | — | 1 | ||
| Pancreatic fistula | D010185 | — | 1 | — | — | — | 1 | ||
| Intestinal diseases | D007410 | HP_0002242 | K63.9 | — | 1 | — | — | — | 1 |
| Merkel cell carcinoma | D015266 | EFO_1001471 | C4A | — | 1 | — | — | — | 1 |
| Peptic esophagitis | D004942 | EFO_1001095 | — | 1 | — | — | — | 1 | |
| Esophagitis | D004941 | HP_0100633 | K20 | — | 1 | — | — | — | 1 |
| Graves ophthalmopathy | D049970 | EFO_1001466 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Insulin resistance | D007333 | EFO_0002614 | — | — | — | — | 1 | 1 | |
| Glucose intolerance | D018149 | HP_0000833 | R73.03 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | LAPYRIUM |
| INN | lapirium chloride |
| Description | Lapyrium chloride is a fatty acid ester. |
| Classification | Small molecule |
| Drug class | quaternary ammonium derivatives |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CCCCCCCCCCCC(=O)OCCNC(=O)C[n+]1ccccc1 |
Identifiers
| PDB | — |
| CAS-ID | 6272-74-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201786 |
| ChEBI ID | — |
| PubChem CID | 22660 |
| DrugBank | — |
| UNII ID | 732T8851QH (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 31 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
5,301 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more